Full Text View
Tabular View
No Study Results Posted
Related Studies
Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy
This study has been completed.
First Received: January 20, 2009   No Changes Posted
Sponsored by: University of Aarhus
Information provided by: University of Aarhus
ClinicalTrials.gov Identifier: NCT00825617
  Purpose

Several studies have demonstrated that Turner Syndrome patients have elevated liver enzymes readily suppressible by a short course of HRT. We wanted to estimated quantitative liver functions in a young group of Turner syndrome patients compared to a healthy control group.


Condition Intervention
Turner Syndrome
Drug: Hormone replacement therapy

Genetics Home Reference related topics: Turner syndrome
MedlinePlus related topics: Hormone Replacement Therapy Turner Syndrome
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Crossover Assignment
Official Title: Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • quantitative liver function tests [ Time Frame: 1996-1999 ] [ Designated as safety issue: No ]

Enrollment: 16
Study Start Date: October 1996
Study Completion Date: June 2000
Primary Completion Date: October 1999 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
HRT: Experimental
Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
Drug: Hormone replacement therapy
Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)

Detailed Description:

Turner syndrome is due to the absence of a part of or the entire X chromosome in females. Stature is short, and morbidity is increased due to risk of osteoporosis and fractures, type 2 diabetes, ischemic heart disease, hypertension, and stroke, but also the risk of cirrhosis is increased. Clinical studies have shown a frequent occurrence of elevated liver enzymes, primarily alanine aminotransferase, g-glutamyl-transferase, and alkaline phosphatase, while bilirubin is normal.

We and others have shown a normalizing effect of hormone replacement therapy (HRT), containing 17bestradiol and a gestagen, on liver enzymes, which may point towards a protective effect on hepatocyte integrity. Marked architectural changes, including nodular regenerative hyperplasia, multiple focal nodular hyperplasia and cirrhosis are observed in some patients and are associated with a risk of liver-related complications. These changes are frequently associated with vascular disorders such as obliterative portal venopathy, probably related to congenitally abnormal vessels. Steatosis, steatofibrosis, and steatohepatitis are seen and may be caused by metabolic disorders. In addition, bile duct alterations resembling small duct sclerosing cholangitis are observed in several patients. Presently, it is not known whether these perturbations in liver morphology and in liver-derived enzymes are related to functional defects in females with TS and whether this may change by HRT. To further explore quantitative liver function in TS, we examined adult women with TS on and off HRT and compared them with a control group of age matched normal women. We used the galactose elimination capacity to assess hepatocyte cytosol activity, the plasma clearance of indocyanine green to assess hepatic blood flow and excretory liver cell function independently of hepatic blood flow, the antipyrine plasma clearance to estimate hepatic microsomal system activity, and the functional hepatic nitrogen clearance to assess mitochondrial- cytosolic metabolic capacity for conversion of amino-nitrogen.We assumed that one or more these metabolic liver functions would be diminished in untreated TS and normalized by HRT. Our principal objective was to understand mechanistically how HRT improves liver function in TS.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Turner syndrome by karyotype

Exclusion Criteria:

  • Thyroid abnormality
  • Glucocorticoid treatment
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00825617

Locations
Denmark, Jutland
Medical department M and Investigational Laboratories
Aarhus C, Jutland, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Investigators
Principal Investigator: J S Christíansen, Professor Medical departmnet M, Aarhus University Hospital, NBG, Denamrk,
  More Information

No publications provided

Responsible Party: Medical department M, Aarhus University Hospital, Denmark ( MD, PhD, DMSc Claus H. Gravholt )
Study ID Numbers: 19963561
Study First Received: January 20, 2009
Last Updated: January 20, 2009
ClinicalTrials.gov Identifier: NCT00825617     History of Changes
Health Authority: Denmark: Danish Dataprotection Agency;   Denmark: Danish Medicines Agency;   Denmark: Ethics Committee

Keywords provided by University of Aarhus:
TS
HRT
Liver function tests

Study placed in the following topic categories:
Gonadal Disorders
Hormone Antagonists
Genital Dwarfism
Estradiol valerate
Hormones, Hormone Substitutes, and Hormone Antagonists
Chromosome Disorders
Endocrine System Diseases
Estradiol 17 beta-cypionate
Ovarian Dwarfism
Hormones
Sex Differentiation Disorders
Estradiol
Monosomy X
Turner Syndrome
Urogenital Abnormalities
Genetic Diseases, Inborn
Norethindrone
Estradiol 3-benzoate
Endocrinopathy
Polyestradiol phosphate
Congenital Abnormalities
Norethindrone acetate
Gonadal Dysgenesis

Additional relevant MeSH terms:
Disease
Gonadal Disorders
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Chromosome Disorders
Endocrine System Diseases
Hormones
Sex Differentiation Disorders
Pharmacologic Actions
Turner Syndrome
Urogenital Abnormalities
Pathologic Processes
Genetic Diseases, Inborn
Syndrome
Sex Chromosome Disorders
Congenital Abnormalities
Gonadal Dysgenesis

ClinicalTrials.gov processed this record on May 07, 2009